Ozempic-maker's shares plunge after failed Alzheimer's trial

Novo Nordisk's Ozempic pill has failed to demonstrate efficacy in slowing the progression of Alzheimer's disease in two clinical trials, leading to a significant decline in the company's stock value. This disappointing outcome was reported by Naomi Kresge on Bloomberg Television.

Shares of Novo Nordisk have significantly declined following the announcement that its Ozempic pill did not slow the progression of Alzheimer’s disease in two major studies. This news comes amid broader economic concerns, including a drop in German business morale as the country struggles to recover from two years of economic contraction.

The stock market opened higher on November 24, 2025, with the Nasdaq and S&P 500 indices showing positive movement. However, shares of Novo Nordisk plummeted after the company's Ozempic medication failed to demonstrate efficacy in slowing Alzheimer's disease progression in clinical trials.

Novo Nordisk's stock has experienced a significant decline following the announcement that its diabetes and weight loss medication, Ozempic, failed to demonstrate any meaningful reduction in the progression of Alzheimer's disease in clinical trials. This disappointing outcome has raised concerns about the company's future prospects in the pharmaceutical market.

Novo Nordisk's shares have significantly declined following the announcement that its Ozempic medication failed to slow the progression of Alzheimer's disease in two major clinical trials. This outcome represents a substantial setback for one of Europe's largest listed companies, which had high hopes for the drug's efficacy in treating this debilitating condition.

Hundreds of jobs are at risk as a major metals recycling giant approaches liquidation, according to a report by Sky News. The company, facing significant financial difficulties, is on the brink of shutting down operations, which could have widespread implications for its workforce and the industry as a whole.

European stocks remained steady, recovering from losses primarily caused by a significant drop in Novo Nordisk A/S shares following the failure of its Ozempic pill in Alzheimer's trials. Investors are also closely monitoring potential peace negotiations between Ukraine and Russia, which could impact market dynamics.

The owner of the Daily Mail is currently in negotiations to acquire the Daily Telegraph and its Sunday counterpart for £500 million, a move that could resolve the uncertainty surrounding these titles that has persisted for over two years.